从保险公司数据库中确定的他汀类药物干预对接受抗癌药物治疗患者周围神经病变的影响。

Influence of statin intervention on peripheral neuropathy in patients treated with anticancer drugs identified from the insurer database.

作者信息

Aizawa Fuka, Yagi Kenta, Sato Maki, Niimura Takahiro, Goda Mitsuhiro, Izawa-Ishizawa Yuki, Ishizawa Keisuke

机构信息

Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.

Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.

出版信息

J Pharm Health Care Sci. 2025 Apr 7;11(1):27. doi: 10.1186/s40780-025-00428-3.

DOI:10.1186/s40780-025-00428-3

PMID:40197323

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11978124/

Abstract

BACKGROUND

Statins, hydroxymethylglutaryl-CoA reductase inhibitors, possess neuroprotective properties. Given the potential neuroprotective properties of statins and their prevalent use in clinical settings, we aimed to investigate their impact on chemotherapy-induced peripheral neuropathy (CIPN) in Japan by assessing both their safety and efficacy in this context.

METHODS

We conducted a retrospective observational study using the Japan Medical Data Centre database, which includes data from 2005 to 2021. We included patients who underwent anticancer therapy and were categorized into non-statin (10,920) and statin (1,537) groups. These groups were matched using a propensity score, resulting in 2,548 non-statin and 1,274 statin users. The primary endpoints were the incidence of CIPN post-first prescription of each anticancer drug and overall survival.

RESULTS

Treatment with statins did not increase the incidence of CIPN (non-statin 27.2% vs. statin 28.4%, P = 0.443). Nevertheless, the incidence of CIPN was significantly high among women (non-statin 28.0% vs. statin 33.2%, P = 0.025). Overall survival was not impacted by statin use (hazard ratio 0.98, 95%CI: 0.83-1.16, P = 0.8846). Among men treated with paclitaxel, we observed an improvement in overall survival (hazard ratio: 0.72; 95% CI: 0.56-0.92; P = 0.0110).

CONCLUSIONS

The use of statins in patients with cancer was not associated with CIPN incidence. However, in men receiving paclitaxel treatment, statins may be linked to improved overall survival. Further studies are necessary to clarify the factors influencing prognosis and CIPN severity.

摘要

背景

他汀类药物，即羟甲基戊二酰辅酶A还原酶抑制剂，具有神经保护特性。鉴于他汀类药物潜在的神经保护特性及其在临床环境中的广泛应用，我们旨在通过评估他汀类药物在此背景下的安全性和有效性，来研究其对日本化疗引起的周围神经病变（CIPN）的影响。

方法

我们使用日本医疗数据中心数据库进行了一项回顾性观察研究，该数据库包含2005年至2021年的数据。我们纳入了接受抗癌治疗的患者，并将其分为非他汀类药物组（10920例）和他汀类药物组（1537例）。使用倾向评分对这些组进行匹配，最终得到2548例非他汀类药物使用者和1274例他汀类药物使用者。主要终点是每种抗癌药物首次处方后CIPN的发生率和总生存期。

结果

使用他汀类药物治疗并未增加CIPN的发生率（非他汀类药物组为27.2%，他汀类药物组为28.4%，P = 0.443）。然而，女性中CIPN的发生率显著较高（非他汀类药物组为28.0%，他汀类药物组为33.2%，P = 0.025）。他汀类药物的使用对总生存期没有影响（风险比0.98，95%置信区间：0.83 - 1.16，P = 0.8846）。在接受紫杉醇治疗的男性中，我们观察到总生存期有所改善（风险比：0.72；95%置信区间：0.56 - 0.92；P = 0.0110）。